搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Pyrococcus horikoshii UPF0290 protein PH0343 (PH0343), partial CSB-YP527580FHX1
CSB-EP527580FHX1
CSB-BP527580FHX1
CSB-MP527580FHX1
CSB-EP527580FHX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Cobalamin synthase (cobS), partial CSB-YP527581FHX1
CSB-EP527581FHX1
CSB-BP527581FHX1
CSB-MP527581FHX1
CSB-EP527581FHX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii tRNA (cytidine (56)-2'-O)-methyltransferase CSB-YP527582FHX
CSB-EP527582FHX
CSB-BP527582FHX
CSB-MP527582FHX
CSB-EP527582FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Putative ribonuclease VapC4 (vapC4) CSB-YP527583FHX
CSB-EP527583FHX
CSB-BP527583FHX
CSB-MP527583FHX
CSB-EP527583FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Uncharacterized ATP-binding protein PH0541 (PH0541) CSB-YP527584FHX
CSB-EP527584FHX
CSB-BP527584FHX
CSB-MP527584FHX
CSB-EP527584FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Glyoxylate reductase (gyaR) CSB-YP527585FHX
CSB-EP527585FHX
CSB-BP527585FHX
CSB-MP527585FHX
CSB-EP527585FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Cysteine--tRNA ligase (cysS) CSB-YP527586FHX
CSB-EP527586FHX
CSB-BP527586FHX
CSB-MP527586FHX
CSB-EP527586FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Phenylalanine--tRNA ligase alpha subunit (pheS) CSB-YP527587FHX
CSB-EP527587FHX
CSB-BP527587FHX
CSB-MP527587FHX
CSB-EP527587FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Pyruvate synthase subunit porB (porB) CSB-YP527588FHX
CSB-EP527588FHX
CSB-BP527588FHX
CSB-MP527588FHX
CSB-EP527588FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Putative transcriptional regulatory protein PH0763 (PH0763) CSB-YP527589FHX
CSB-EP527589FHX
CSB-BP527589FHX
CSB-MP527589FHX
CSB-EP527589FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii UPF0148 protein PH0795 (PH0795) CSB-YP527590FHX
CSB-EP527590FHX
CSB-BP527590FHX
CSB-MP527590FHX
CSB-EP527590FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Uncharacterized protein PH0856 (PH0856) CSB-YP527591FHX
CSB-EP527591FHX
CSB-BP527591FHX
CSB-MP527591FHX
CSB-EP527591FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii DNA double-strand break repair Rad50 ATPase (rad50), partial CSB-YP527592FHX
CSB-EP527592FHX
CSB-BP527592FHX
CSB-MP527592FHX
CSB-EP527592FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Probable molybdenum cofactor guanylyltransferase (mobA) CSB-YP527593FHX
CSB-EP527593FHX
CSB-BP527593FHX
CSB-MP527593FHX
CSB-EP527593FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii UPF0310 protein PH1033 (PH1033) CSB-YP527594FHX
CSB-EP527594FHX
CSB-BP527594FHX
CSB-MP527594FHX
CSB-EP527594FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii DNA-binding protein PH1060 (PH1060) CSB-YP527595FHX
CSB-EP527595FHX
CSB-BP527595FHX
CSB-MP527595FHX
CSB-EP527595FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Probable methylcobalamin:homocysteine methyltransferase (metE) CSB-YP527596FHX
CSB-EP527596FHX
CSB-BP527596FHX
CSB-MP527596FHX
CSB-EP527596FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii tRNA (uracil (54)-C (5))-methyltransferase CSB-YP527597FHX
CSB-EP527597FHX
CSB-BP527597FHX
CSB-MP527597FHX
CSB-EP527597FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii UPF0098 protein PH1269 (PH1269) CSB-YP527598FHX
CSB-EP527598FHX
CSB-BP527598FHX
CSB-MP527598FHX
CSB-EP527598FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii UPF0212 protein PH1312 (PH1312) CSB-YP527599FHX
CSB-EP527599FHX
CSB-BP527599FHX
CSB-MP527599FHX
CSB-EP527599FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>